Barclays
CTNM

Barclays’s Contineum Therapeutics CTNM Stock Holding History

Barclays’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$574K Sell
43,958
-15,549
-26% -$209K ﹤0.01% 3107
2025
Q4 		$680K Buy
59,507
+53,031
+819% +$605K ﹤0.01% 3681
2025
Q3 		$76.1K Buy
6,476
+4,744
+274% +$38.2K ﹤0.01% 4681
2025
Q2 		$6.88K Sell
1,732
-9,351
-84% -$40.6K ﹤0.01% 4944
2025
Q1 		$77.4K Sell
11,083
-5,203
-32% -$47.3K ﹤0.01% 4480
2024
Q4 		$239K Buy
16,286
+7,978
+96% +$126K ﹤0.01% 4222
2024
Q3 		$159K Buy
8,308
+5,925
+249% +$114K ﹤0.01% 4411
2024
Q2 		$42K Buy
+2,383
New +$38.4K ﹤0.01% 4271

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's CTNM Position: Q1 2026 in Review

Barclays reduced its Contineum Therapeutics (CTNM) stake by 26% in Q1 2026, selling an estimated $209K and leaving 43,958 shares worth $574K. The position accounts for ﹤0.01% of the portfolio, ranked #3107.

Barclays first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $680K in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Barclays held 43,958 shares of Contineum Therapeutics worth $574K as of Q1 2026.
  • Barclays sold 15,549 Contineum Therapeutics shares in Q1 2026, an estimated $209K.
  • Contineum Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3107 holding.
  • Barclays first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Barclays's Contineum Therapeutics position peaked at $680K in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.